ecteinascidin 743 has been researched along with Leukemia, Lymphocytic, Chronic, B-Cell in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babu, V; Biersack, B; Bloehdorn, J; Chessa, L; Crispatzu, G; Efremov, DG; Hallek, M; Herling, CD; Herling, M; Knittel, G; Lohmann, G; Mayer, P; Muenzner, JK; Prinz, C; Reinart, N; Reinhardt, HC; Schneider, JI; Schobert, R; Schumacher, B; Stilgenbauer, S; Vasyutina, E | 1 |
1 other study(ies) available for ecteinascidin 743 and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
Topics: Animals; Apoptosis; Cell Line, Tumor; Clinical Trials as Topic; Dioxoles; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 2017 |